Comparison of case and control intervals characteristics from 251 GLADEL patients
| Characteristics | Case (increased SDI) (n=287) | Control (no change in SDI) (n=287) | p Value |
|---|---|---|---|
| Disease duration, years, mean (SD) | 2.78 (1.80) | 3.20 (1.72) | 0.005 |
| Adjusted mean SLEDAI, mean (SD) | 8.62 (6.55) | 7.67 (5.48) | 0.060 |
| Length of the interval, years, mean (SD) | 1.18 (0.72) | 1.12 (0.54) | 0.317 |
| Number of flares, mean (SD) | 0.75 (0.66) | 0.37 (0.54) | <0.001 |
| Number of mild-moderate flares, mean (SD) | 0.49 (0.63) | 0.29 (0.48) | <0.001 |
| Number of severe flares, mean (SD) | 0.25 (0.47) | 0.08 (0.27) | <0.001 |
| Cumulative dose of prednisone, grams (SD) | 27.3 (24.5) | 29.2 (24.1) | 0.348 |
| Use of antimalarials (%) | 203 (70.7) | 16 (75.3) | 0.222 |
| Use of any immunosupressor (%) | 214 (74.6) | 222 (77.4) | 0.435 |
| Use of cyclophosphamide (%) | 156 (54.4) | 157 (54.7) | 0.933 |
| Use of azathioprine (%) | 109 (38.0) | 119 (41.5) | 0.394 |
| Use of methotrexate (%) | 25 (8.7) | 26 (9.1) | 0.883 |
| Use of mycophenolate mofetil (%) | 5 (1.7) | 7 (2.4) | 0.560 |
| Use of cyclosporine (%) | 9 (3.1) | 10 (3.5) | 0.816 |
| Use of leflunomide (%) | 2 (0.7) | 2 (0.7) | 1.000 |
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.